The medication is commonly used to provide symptomatic support for conditions related to microbial involvement and excessive skin scaling, helping to manage symptoms that interfere with daily comfort. The product is indicated for the treatment and prevention of seborrhoeic dermatitis and pityriasis capitis (dandruff). It is applied across domains where additional symptomatic support is needed in conditions linked to yeast and fungal overgrowth, including Pityriasis Versicolor.

Primary Therapeutic Focus

The formulation is relevant in situations involving symptomatic discomfort and is commonly used to help address symptom clusters that may become intense or disruptive, including manifestations such as intense itching (pruritus), redness (erythema), and chronic flaking. The medicine is applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden and helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: Symptomatic Support for Chronic Conditions

Domain	Key Symptom Clusters Addressed	Benefit Focus
Dermatological Fungal	Chronic flaking, scaling, visible redness	Support during difficult episodes
Antiseborrheic	Intense itching, irritation, recurrent symptoms	Contributes to maintaining stability

Who Can and Cannot Use Keto plus?

The official eligibility for the topical combination product Keto plus (Ketoconazole/Pyrithione Zinc) is strictly defined by regulatory documents, focusing on absolute exclusions and age-related restrictions.

Eligibility Status	Defined Regulatory Rule
Absolute Contraindication	Individuals with a known hypersensitivity or allergy to Ketoconazole, Pyrithione Zinc, or any excipient in the formulation.
Established Use	Generally approved for use in adults and adolescents aged 12 years and over.
Pediatric Restriction	Safety and effectiveness have not been established in children younger than 12 years of age.
Local Restriction	The shampoo is contraindicated for use on a scalp that is broken or inflamed.
Conditional Use	Pregnancy and Lactation: Use is conditional. While not formally contraindicated due to minimal systemic absorption, the official label recommends caution as adequate, controlled studies in these populations are lacking.

The official eligibility profile establishes a primary exclusion for allergic history and places strict limitations on pediatric use due to insufficient study data. Patients transitioning from prolonged topical steroid treatment are advised to gradually withdraw the steroid to prevent a potential rebound effect. The topical formulation does not carry the same systemic organ function restrictions as the oral medicine.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile for Keto plus (topical Ketoconazole and Pyrithione Zinc) is distinguished by the absence of documented systemic interactions in official government regulatory information. This finding is based on the minimal systemic absorption achieved when the product is applied topically.

Regulatory documents, including those from the U.S. Food and Drug Administration (FDA) and European national authorities, consistently conclude that plasma concentrations of Ketoconazole are typically non-detectable following the use of the topical shampoo or cream.

Category	Regulatory Status for Topical Use
Documented Drug-Drug Interactions	None listed in official labeling
Contraindicated Combinations	None listed based on interaction risk
CYP Enzyme Interactions	None documented due to minimal systemic exposure
Timing-Separation Rules	None mandated with other medicinal products

Consequently, the official prescribing information does not list specific restrictions for co-administration with other systemic medicines. The extensive list of severe drug interactions associated with the oral formulation of Ketoconazole (due to potent inhibition of the CYP3A4 enzyme) is not applied to the topical product in regulatory summaries. This structure is upheld because the overall risk of pharmacokinetic or pharmacodynamic interactions with other substances is considered negligible under labeled conditions of use.

Keto plus modulates cellular metabolism by inducing a state of nutritional ketosis, primarily by shifting the primary substrate for adenosine triphosphate (ATP) production from glucose to fatty acids and subsequent ketone bodies. This systemic shift is achieved through a reduction in circulating glucose, leading to enhanced hepatic beta-oxidation of fatty acids.

The resulting increase in the primary ketone body, beta-hydroxybutyrate (betaHB), allows it to function beyond an energy substrate. betaHB acts as an endogenous histone deacetylase (HDAC) inhibitor, leading to increased acetylation of histone and non-histone proteins. This modification modulates gene transcription in various tissues, affecting the expression of genes involved in oxidative stress and inflammatory signaling pathways.

Furthermore, the metabolic change inhibits the mammalian target of rapamycin (mTOR) signaling pathway by increasing the activity of AMP-activated protein kinase (AMPK), a key intracellular energy sensor. This upstream modulation consequently alters cellular processes related to growth and protein synthesis. These biochemical and intracellular cascades result in system-level physiological modulation of energy homeostasis and cellular redox balance.

The administration of Keto plus, a combination product containing Ketoconazole and Pyrithione Zinc, is strictly confined to the topical route on the affected skin and scalp. There is a structured approach for its application, frequency, and duration.

For the initial management of seborrheic dermatitis and dandruff, the product is applied on a twice-weekly schedule, typically maintaining a minimum interval of three days between applications. The standard treatment course is generally limited to a duration of up to four consecutive weeks. Following the initial phase, the usage pattern transitions to an intermittent maintenance schedule, often recommended as once weekly or once every one to two weeks. In the context of Pityriasis Versicolor, the protocol involves a single application only, using the 2% formulation.

Proper use involves a specific contact time: the shampoo must be applied to the damp affected area, lathered, and left in place for three to five minutes before being thoroughly rinsed with water. A key procedural instruction addresses patients transitioning from other therapies: it requires a gradual withdrawal of existing topical corticosteroids over a period of two to three weeks upon initiation to manage potential effects. Regarding specific populations, use in children under the age of two years is not routinely recommended without consulting a physician.

Research evidence / Overview of Studies for Keto plus

Evidence for Use in Seborrhoeic Dermatitis

The use of Ketoconazole and Pyrithione Zinc in formulations like Keto plus was studied in the context of conditions characterized by seborrhoeic dermatitis, a condition characterized by fluctuating or episodic manifestations, including scaling, itching, and redness. The research base primarily consists of short-term Randomized Controlled Trials (RCTs) and controlled comparative trials that examined the product's active ingredients against inactive treatments and other single-ingredient monotherapies.

Researchers evaluated outcomes related to physical discomfort, such as the overall severity of the condition, and also measured the reduction of specific symptoms like scaling, redness, and patient-reported outcomes. The research contributes to the broader evidence landscape by describing how symptoms were observed to evolve in the studied populations during the two-to-four-week time intervals. The evidence base for this indication is derived from controlled trials, but comparative evidence is lacking for the precise combination versus single active components over extended periods.

Evidence for Use in Pityriasis Capitis (Dandruff)

Research explored whether formulations containing these active ingredients had an effect on Pityriasis Capitis, or common dandruff, in randomized, controlled clinical trials. These studies examined outcomes related to scaling and flaking, specifically focusing on flaking and overall scalp condition. Studies report how symptoms evolved in the observed populations, and the data show patterns related to changes in scaling and the presence of scalp yeast.

While the evidence base for formulations containing Ketoconazole for dandruff is based on controlled trials, data are still emerging regarding the consistent long-term stability of the scalp after treatment ends. Follow-up durations were limited to short post-treatment observation periods, and there is limited information for long-term outcomes that fully characterize recurrence cycles.

Key Research Gaps and Uncertainties

Long-term effects are not fully established, particularly concerning relapse rates and the utility of long-term maintenance protocols using this specific product. Comparative evidence is lacking for the specific combination of Ketoconazole and Pyrithione Zinc against other dual-active or alternative single-active formulations over intermediate to long time periods. Furthermore, evidence is limited for use in younger children, the elderly, or in patients with complex comorbid dermatological conditions. The research provides context but not individual predictions; the study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References Tinea Versicolor - StatPearls (Topical treatment options, including Zinc Pyrithione)

Common questions about Keto plus (FAQ)

Q: What is the main difference between Keto plus and other common weight-management drugs?

A: Keto plus is officially classified by regulatory documents as a topical antifungal and antiseborrheic agent. It contains Ketoconazole and Pyrithione Zinc and is used strictly for affected skin and scalp conditions. The drug's classification and therapeutic purpose are entirely different from systemic weight-management drugs.

Q: Is Keto plus considered a long-term treatment option?

A: Regulatory guidance defines the initial treatment for active conditions as typically lasting up to four consecutive weeks. Following the initial phase, usage patterns described in official documents transition toward an intermittent maintenance schedule. Official documents note, however, that long-term effects and the utility of long-term maintenance protocols are not fully established in the current body of research.

Q: What happens when a person stops taking Keto plus?

A: Official label information advises on the management of topical corticosteroids: a gradual withdrawal of existing topical steroids is described when initiating this medicine. Research summaries note that the follow-up periods in studies were limited, and there is limited information available on long-term outcomes that characterize recurrence cycles after treatment ends.

Q: Is it possible to become dependent on Keto plus after using it for a long time?

A: The official regulatory classification of this topical antifungal preparation is not associated with abuse or dependence potential. This product is not listed as a controlled substance in official drug schedules.

Q: Can people with mild kidney issues use Keto plus?

A: Official eligibility information notes that because the topical shampoo has minimal systemic absorption, resulting in typically non-detectable plasma concentrations, the product does not carry the same systemic organ function restrictions that are associated with the oral form of Ketoconazole.

Q: Why do some people experience initial nausea when starting Keto plus?

A: Nausea is not listed as a Common or Uncommon side effect associated with the topical shampoo in official regulatory documents. The most frequently documented effects relate to the application site and include local reactions such as itching, a burning sensation, and redness.

Q: Is it typical for users to experience headaches when first starting Keto plus?

A: Headache is not listed as a Common or Uncommon adverse reaction associated with the topical shampoo in official regulatory documents. Side effects reported during clinical experience are primarily related to local skin and scalp reactions, such as application site irritation.

Q: What is the typical duration of treatment with Keto plus as described in clinical guidelines?

A: For the initial management of active conditions like seborrhoeic dermatitis, the standard treatment course is generally limited to a duration of up to four consecutive weeks. The product is typically applied on a twice-weekly schedule during this period.

Q: Do regulatory agencies classify Keto plus as having a potential for abuse?

A: Regulatory agencies classify this product as a topical antifungal that is not scheduled as a controlled substance in official drug lists, indicating it does not have a documented potential for abuse.

Q: Is it true that taking Keto plus requires regular blood tests?

A: No routine systemic laboratory monitoring or blood tests are mandated in the official prescribing information for the topical shampoo. Regulatory documents state that systemic absorption is minimal, and plasma concentrations are typically non-detectable following its use.

Q: Can people with diabetes be prescribed Keto plus?

A: Official information indicates that due to minimal systemic absorption, the official label does not list systemic conditions, such as diabetes, as a formal contraindication or special precaution for its use.

Q: What is the reason for the different possible dose strengths of Keto plus?

A: Different strengths of the formulation are often noted in official documents for use in different indications. For example, a specific strength is often noted for use in Pityriasis Versicolor, compared to the formulations used for seborrheic dermatitis.

Q: Can Keto plus be used by people who are vegetarian or vegan?

A: Official regulatory documents provide a full list of excipients (inactive ingredients) contained in the formulation. However, regulatory documents do not provide a formal classification of the product as vegetarian or vegan based on its excipient list. The full list of inactive ingredients is available in the official labeling.

Q: Is there a certain time of day that is best to take Keto plus?

A: Regulatory documents specify the required frequency (e.g., twice-weekly) and the required contact time on the scalp (three to five minutes). The official guidance does not mandate a specific time of day (morning or evening) for application.

Q: Are there any specific foods or drinks that should be avoided while on Keto plus?

A: Regulatory documents state there is an absence of documented systemic interactions due to the minimal systemic absorption of the topical product. Consequently, there are no specific restrictions or avoidance warnings listed in regulatory documents regarding foods or drinks.

Q: Can Keto plus affect my ability to get pregnant?

A: Official prescribing information notes that adverse effects on the foetus or breast-fed children are generally not anticipated due to minimal systemic absorption. Information specifically detailing the effect on a user's fertility for the topical product is not generally included in the official regulatory label.

Q: Is Keto plus approved in countries outside of the United States?

A: The drug's active ingredients and combination are approved for use in multiple jurisdictions globally. Regulatory oversight is provided by organizations such as the EMA (European Medicines Agency) and various national government bodies.

Q: What are the key points from the major research study on Keto plus?

A: The research evidence section outlines that studies primarily involved short-term randomized controlled trials (RCTs). These trials examined the active ingredients against inactive treatments and focused on outcomes such as overall condition severity and the reduction of specific symptoms like scaling and redness.

Q: Is there research evidence supporting the use of Keto plus in adolescents?

A: The official eligibility is generally established for use in adults and adolescents aged 12 years and over. Regulatory documents confirm that safety and efficacy data were considered sufficient for the shampoo formulation's use in this age group.

Q: Does Keto plus have an effect on blood pressure?

A: Due to the minimal systemic absorption from topical use, resulting in non-detectable plasma concentrations, effects on systemic functions like blood pressure are not listed or anticipated in the official prescribing information.

Q: Are there any documented drug-drug interactions with common pain relievers and Keto plus?

A: Official regulatory information concludes that the prescribing information does not list specific restrictions or drug-drug interactions with other systemic medicines, including common pain relievers. This is upheld due to the minimal systemic exposure achieved with the topical product.

Q: Does Keto plus have any known interaction with caffeine?

A: Regulatory documents state there is an absence of documented systemic interactions due to the minimal absorption of the topical product. Consequently, there are no specific restrictions or warnings listed regarding caffeine.

Q: Is it normal to feel a change in appetite after starting Keto plus?

A: A change in appetite is not listed as a Common or Uncommon side effect associated with the topical shampoo in official regulatory documents. The documented adverse reactions are primarily local skin and scalp reactions.

Q: Does Keto plus have a specific designation, like 'Schedule IV,' in drug classifications?

A: The topical product is classified as an antifungal and is not designated as a controlled substance (e.g., Schedule I, II, III, IV, or V) by official drug enforcement agencies.

The official storage and disposal requirements for this topical antifungal product are defined to maintain its chemical stability and ensure public safety.

Required Storage and Protection

Requirement	Description (Per Official Labeling)
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 25 C (77 F).
Protection	Must be protected from light and moisture. Do not allow the product to freeze.
Container	Keep the product in its original container and ensure the cap or container is tightly closed.

Child Safety and Waste Disposal

The medicine must be kept out of the sight and reach of children. Use only before the expiration date printed on the label.

Disposal should prioritize an authorized drug take-back program. If one is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a bag for household trash; it should not be flushed down a drain or toilet.